The European Union’s new institutional mandate has created new hope among cosmetics industry stakeholders that a planned revision of the Cosmetic Products Regulation (CPR) will be relatively light, if it happens at all. “We’ll need to see whether the CPR [revision] is proposed, when that is and, crucially for our sector, whether it’s along the lines of what was discussed in the previous cycle,” said John Chave, Cosmetics Europe director-general, in a 20 September interview.
EU Revision Of Cosmetic Products Regulation Uncertain In New Institutional Cycle
Cosmetics Europe hopes a more “competitive” spirit will define the 2024-2029 regime. Director-general John Chave discusses the association’s outlook on planned revisions to REACH and the Cosmetic Products Regulation in the new EU institutional mandate.
More from Regulation
• By
Single-use packaging producers subject to California’s SB 54 recycling law, which implements a statewide EPR plan, should continue to prepare for its implementation, even as they enter a ‘prolonged period of uncertainty,’ says consultant Michael Washburn.
• By
Counterfeit beauty products cost the US industry an estimated $3bn in 2023, says a trade expert during the Personal Care Products Council’s Beauty Collective Summit.
• By
Cosmetics companies brace for the impact of Trump administration tariffs as industry experts seeing an opportunity for an exemption urge stakeholders to reach out to lawmakers. The issue was discussed during PCPC’s recent Beauty Collective Summit.
• By
The Washington Department of Ecology releases its formal draft rule under the Toxic Free Cosmetics Act listing 28 intentionally added formaldehyde releasers, with plans to adopt the rule this summer.
More from Interviews
• By
HBW Insight speaks to food supplement market experts about what manufacturers should be looking out for over the coming year.
• By
HBW Insight speaks to consumer healthcare industry associations around the globe, which offer their predictions for the year ahead.
• By
HBW Insight speaks to leaders at US consumer health product trade groups and food and drug regulation consultants and attorneys who offer their predictions for the year ahead.